MSD supports World IBD Day

Lucerne, May 15, 2018 - Saturday May 19 is World IBD Day. It aims to support an increase in global understanding and awareness amongst the public for people with chronic inflammatory bowel diseases. In Switzerland, World IBD Day is being coordinated by the Swiss Morbus Crohn/Ulcerative Colitis Society (SMCCV). Already for the second time, MSD is supporting activities in Switzerland as official partner.

IBD (inflammatory bowel diseases) refers to continuous inflammatory diseases of the bowel.1 The two most common manifestations are Morbus Crohn and ulcerative colitis.1 More than 25,000 people in Switzerland are affected by it.2 The introduction of biological drugs in recent years has achieved great advances in the treatment of IBD patients.3 Nevertheless, there is no cure for Morbus Crohn and ulcerative colitis and the psychological strain on patients is often still very high2. Symptoms such as blood in the stools, diarrhea and tiredness make it hard for patients to live a normal life2.

Education and raising awareness on May 19 in Solothurn

On the occasion of world IBD day on May 19, the Swiss Morbus Crohn/Ulcerative Colitis Society (SMCCV) is this year once again taking a strong, symbolically purple, stand for people in Switzerland affected by chronic inflammatory bowel diseases. From 9:00 to 4:00 PM, visitors to the Solothurn country house will find out a lot of worthwhile information on this subject. In addition to exciting specialist talks by renowned speakers, there will also be a photo wall with a purple ribbon and a view into the largest model of a bowel in Europe. Above all, World IBD Day also gives the opportunity to those affected by the condition to meet each other and talk amongst themselves.

MSDs commitment to the fight against IBD

For years, MSD has been highly committed to researching new and improved treatment options for IBD patients. To develop innovative solutions that contribute towards the improved health of patients in Switzerland, MSD is continuously searching for cooperation opportunities. An example of the result of such a successful cooperation is IBDialog monthly: a practical app which gives patients in Switzerland with chronic inflammatory bowel diseases and their gastroenterologists a continuous overview of their course of treatment. It was developed by leading gastroenterologists from IBDnet and the patient organization SMCCV in close cooperation with MSD.

References

1 https://www.purpleribbon.ch/was-ist-ced (last access 5/10/2018)

2 http://www.smccv.ch (last access 5/10/2018)

3 Cote-Daigneault J et al "Biologics in inflammatory bowel disease: what are the data? United European Gastroenterology Journal 2015, Vol. 3(5) 419–428

About MSD

MSD is a leading global biopharmaceutical company which has been engaged in life science research for more than a century, developing drugs and vaccines for the most challenging diseases worldwide. MSD is a registered trademark of Merck & Co., Inc., Kenilworth, New Jersey, USA. With our prescription drugs, vaccines, biological therapies, and veterinary products, we offer innovative health solutions in over 140 countries. With wide-ranging programs and partnerships, we are also committed to achieving improved access to healthcare. Today MSD is still at the forefront of research for the prevention and treatment of diseases which threaten people and society around the world, including cancer, cardiovascular diseases, new animal diseases, Alzheimer’s, and infectious diseases, including HIV and Ebola. For more information visit www.msd.com and follow us on Twitter.

MSD Human Medicine Switzerland

Switzerland is a key location for the company, which has 600 employees working there in national and international functions. The Human Medicine division in Switzerland is responsible for the distribution of prescription drugs and biopharmaceuticals in the areas of oncology, diabetes, cardiovascular diseases, infectious diseases (including anti-fungal, antibiotic resistance, HIV/Aids, and hepatitis C), immunology, women’s health as well as vaccines for children, young people, and adults.

MSD is active in clinical research in Switzerland, where the company provides medicines for clinical trials worldwide. Additionally, MSD is committed to raising health literacy and promoting the healthcare economy on a local level. The firm is also active in Lucerne, where the MSD headquarters are located. In 2018 the company received certification as a “Top Employer” in Switzerland for the sixth year in succession, as well as the “Top Employer Europe” award for the third time.

More information is available at: www.msd.ch

Press contact:
Dr. Angelika März, Director Policy & Communications
MSD Merck Sharp & Dohme AG
Tel. +41 58 618 35 18 / Mobile 079 378 02 47
media.switzerland@merck.com

© 2018 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Luzern. All rights reserved.

CORP-1249067-0001, May 2018